PerkinElmer licenses CHO cell line to Trinomab Biotech

By The Science Advisory Board staff writers

February 4, 2021 -- PerkinElmer has licensed its Horizon Discovery Chosource Chinese hamster ovary (CHO)-K1GS knockout cell line to Trinomab Biotech in China to produce a human monoclonal antibody drug candidate to fight tetanus toxin.

Trinomab was able to develop its drug candidate utilizing Horizon's Chosource cell line, including a gene-editing glutamine synthetase knockout CHO K1 cell line and well-established GS expression system. A phase I clinical trial in Australia is expected to be completed in August 2021.

More than nine biotherapeutics expressed in the Chosource cell line have progressed to investigational new drug filings, according to PerkinElmer.

PerkinElmer debuts test kit to expand GPCR therapies
PerkinElmer has debuted new assay kits to help further G protein-coupled receptor (GPCR) drug discovery.
PerkinElmer unveils LC 300 platform, SimplicityChrom software
PerkinElmer has debuted its LC 300 platform and SimplicityChrom software, a package designed to combine high-performance liquid chromatography and ultrahigh-performance...
PerkinElmer debuts ChemOffice+ Cloud
PerkinElmer has introduced ChemOffice+ Cloud, a new application for its ChemDraw chemistry drawing software portfolio.
PerkinElmer to acquire Horizon Discovery for $383M
PerkinElmer has reached an agreement to acquire Horizon Discovery Group with an all-cash offer of approximately $383 million. The transaction is...

Copyright © 2021 scienceboard.net


Conferences
Glasgow International Health Festival
August 24-27
Glasgow, Glasgow City United Kingdom
Pharma Competitive Intelligence Conference and Exhibition
September 21-22
Newark, New Jersey United States
BioProcess International (BPI) Conference
September 27-30
Boston, Massachusetts United States
Laboratory Products Association Annual Meeting
October 1-4
Scottsdale, Arizona United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter